anti-Mullerian hormone AMH fasting state
Selected indexed studies
- A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome. (Clin Endocrinol (Oxf), 2023) [PMID:37265016]
- Anti-Mullerian hormone and cardiometabolic status: a systematic review. (Biomarkers, 2023) [PMID:37309096]
- The impact of intermittent fasting on fertility: A focus on polycystic ovary syndrome and reproductive outcomes in Women-A systematic review. (Metabol Open, 2025) [PMID:39876903]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome. (2023) pubmed
- Anti-Mullerian hormone and cardiometabolic status: a systematic review. (2023) pubmed
- The impact of intermittent fasting on fertility: A focus on polycystic ovary syndrome and reproductive outcomes in Women-A systematic review. (2025) pubmed
- Anti-Müllerian Hormone Accelerates Pathological Process of Insulin Resistance in Polycystic Ovary Syndrome Patients. (2021) pubmed
- Association of anti-Müllerian hormone and insulin resistance in adolescent girls with polycystic ovary syndrome. (2024) pubmed
- Serum anti-Mullerian hormone levels in Turkish girls aged 18 and younger for ovarian reserve determination. (2024) pubmed
- Serum Anti-Mullerian Hormone (AMH) Levels Among Different PCOS Phenotypes and Its Correlation with Clinical, Endocrine, and Metabolic Markers of PCOS. (2023) pubmed
- Anti-mullerian hormone attenuates insulin resistance and systemic inflammation in old obese C57BL/6 male mice. (2021) pubmed
- Hormone profiling, including anti-Müllerian hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes. (2019) pubmed
- Anti-Müllerian hormone was independently associated with central obesity but not with general obesity in women with PCOS. (2022) pubmed